Compare IDEXX Laboratories, Inc. (IDXX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wayfair Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.8× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Wayfair Inc for 8 Days on average.
| IDXX | W | |
|---|---|---|
Market Cap | $40.43B | $14.40B |
Volume | 692,164 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $119.05 |
52-Week Low | $504.70 | $57.40 |
Typical Hold Time | 46 Days | 8 Days |
Enterprise Value | $41.32B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Wayfair (W) trades at $105.89, up 1.36% with bullish technical signals from moving averages. The company shows revenue growth to $12.9B in 2026 but maintains negative net margins around -2.5%. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.904, while Q3 2026 results are pending. Analyst sentiment is positive with 54% buy ratings and a $114.13 consensus target. The stock faces headwinds from high debt-to-asset ratio of 95.11% and persistent unprofitability despite top-line expansion.
Wayfair presents a mixed outlook with strong revenue growth and technical momentum offset by profitability challenges. The primary opportunity lies in continued market share gains and operational efficiency improvements. Key risks include competitive pressures in e-commerce, high leverage, and macroeconomic sensitivity. Investors should weigh the bullish analyst consensus against fundamental weaknesses in margin performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
